NasdaqGM:HROWPharmaceuticals
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy?
In August 2026, Harrow, Inc. reported second-quarter revenue of US$70.66 million versus US$63.74 million a year earlier, swung to a net loss of US$17.27 million, and reiterated its 2026 revenue guidance of US$350 million to US$365 million.
Just days earlier, Harrow agreed to acquire TYRVAYA nasal spray for up to US$100 million, aiming to broaden its dry eye disease franchise with a drop-free treatment that complements its existing VEVYE offering.
Next, we’ll examine how reaffirmed 2026...